Clorox reported better-than-expected Q4 earnings and sales, and provided an FY2027 outlook that largely aligns with market estimates. Following these results, several analysts adjusted their price targets upwards, indicating a moderately positive sentiment for the stock.
Clorox's Q4 results surpassed analyst expectations for both EPS and sales, demonstrating resilience in a 'dynamic environment.' The company's FY2027 guidance for EPS and sales is generally in line with or slightly above market estimates, which is a positive signal for future performance. This performance has led to analysts like Wells Fargo raising their price targets, suggesting a more optimistic outlook for the stock. For traders, this indicates a potential short-term positive momentum for CLX, driven by the earnings beat and analyst upgrades, though the 'Underperform' rating from Evercore ISI Group suggests some lingering caution.